Unknown

Dataset Information

0

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer.


ABSTRACT:

Background

Second-line (2 L) chemotherapies for advanced or metastatic gastric cancer have shown improved survival but there is no commonly accepted standard of care. This study examines real-world patient characteristics, treatment patterns, healthcare resource use (HCRU) and clinical outcomes in this setting.

Methods

Retrospective chart reviews were performed at participating institutions from Australia, Canada, Italy and UK for adult patients receiving 2 L treatment for advanced/metastatic disease from January 2013 to July 2015. Data were collected for 12 months or until death.

Results

Two hundred eighty patients were included, mean age was 60.9 years and 68.9% were male. Half (51.8%) received monotherapy in 2 L, of whom 69.0% received taxanes. Irinotecan monotherapy was common in Australia (30.0% of monotherapy patients) and Canada (43.8%), but infrequent in Italy and UK. Doublet chemotherapy was used in 36.4% of 2 L patients, most commonly fluoropyrimidine + irinotecan. Use of targeted therapies (trastuzumab, ramucirumab) was infrequent except in Italy. Estimated median real-world progression-free survival (rwPFS) and real-world overall survival (rwOS) from the time of 2 L treatment initiation was 3.09 (95% CI: 2.76-3.68) and 6.54 (5.29-7.76) months, respectively, and estimated 12-month rwPFS and rwOS rate was 8 and 26%, respectively. Only a minority (26.8%) of patients were hospitalized during the follow-up period, with the lowest hospitalization in Italy (16.7%). Laboratory and imaging tests were performed for 93.2 and 70.4%, respectively.

Conclusions

About half of patients received monotherapy as 2 L chemotherapy for advanced/metastatic gastric cancer and a third received doublets. Real-world clinical outcomes for 2 L treatment are poor and HCRU is considerable.

SUBMITTER: Gomez-Ulloa D 

PROVIDER: S-EPMC7201990 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7467430 | biostudies-literature
| S-EPMC7397908 | biostudies-literature
| S-EPMC4254868 | biostudies-literature
| S-EPMC6057543 | biostudies-literature
| S-EPMC5391942 | biostudies-literature
| S-EPMC7158109 | biostudies-literature
| S-EPMC8342328 | biostudies-literature
| S-EPMC8450614 | biostudies-literature
| S-EPMC8053791 | biostudies-literature
| S-EPMC6503607 | biostudies-literature